Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Provides a Sustained 48-Week Response, Reducing Serum Uric Acid and Preserving Renal Function in Patients With Uncontrolled Gout (UG) and Stage 3 Chronic Kidney Disease

• ECN Workshop •
• 12 March, 2026 •
• •

The Impact of Elevated Serum Urate Levels and Tophi on HRQOL and Daily Functioning in Patients with Uncontrolled Gout

Angelo Gaffo, Bhavisha Desai, Abiola Oladapo, Nana Kragh, Lauren A. Do, Madeline O'Grady, Naomi Schlesinger

• ASN •
• 6 November, 2025 •
• •

Effect of Nanoencapsulated Sirolimus plus Pegadricase (NASP) on Kidney Outcomes: Results from the Phase 3 DISSOLVE Studies

Minesh Rajpal, Vibeke Strand, Rehan Azeem, Ben Peace, Bhavisha Desai, Richard J. Johnson

Available materials

• ASN •
• 6 November, 2025 •
• •

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Reduces Gout Clinical Manifestations in Patients With Uncontrolled Gout (UG) and Stage 3 CKD

Nissreen Elfadawy, Puja Khanna, Rehan Azeem, Ben Peace, Bhavisha Desai, Yasir Qazi

Available materials

• ASN •
• 6 November, 2025 •
• •

Management of Uncontrolled Gout Among Nephrology Professionals: Findings from a Medical Chart Audit

Hyon Choi, Nana Kragh, Amod Athavale, Bhavisha Desai, Amal Gulaid, Abiola Oladapo, Brittany Smith, Kenneth Saag

Available materials